Curis (CRIS) Q4 2025 Earnings Call Transcript

Curis reported a Q4 non-cash gain of $27.2M from the Erivedge sale producing Q4 net income of $19.4M ($1.23/sh) while FY2025 showed a net loss of $7.6M ($0.58/sh). Management said recurring Erivedge revenue effectively ended in November 2025 and expects cash and equivalents as of 12/31/25 plus $20.2M initial PIPE proceeds (Jan 2026) and up to $20.2M contingent on a CLL dosing milestone should fund operations into 2027. Clinically, TakeAim Lymphoma (PCNSL) enrollment is on track (management guidance: 12–18 months to full enrollment), TakeAim CLL sites are activated with initial proof-of-concept data targeted for ASH in December, and AML triplet data showed 5 of 8 evaluable patients achieved MRD conversion. Key risks: no meaningful near-term revenue and further program expansion depends on milestone or additional financing.

Analysis

The strategic clean-up of legacy income turns the company into a pure, trial-driven story whose valuation now behaves like a short-duration option on clinical readouts and financing milestones. That changes second-order competition: incumbents whose revenue comes from chronic BTK-based care face a potential structural challenge if a time-limited combination demonstrating deep MRD clearance becomes credible, which would shift payer economics and force defensive life-cycle strategies (label expansions, combos, or price concessions).

Milestone-linked financing and enrollment cadence create a fragile funding cliff: rare-disease recruitment is lumpy and unpredictable, so milestone triggers tied to patient-dosing or small-n threshold events amplify dilution risk if enrollment slips. Regulators historically accept single-arm ORR-driven accelerated paths in narrow indications, but the need for confirmatory evidence means a positive early readout only compresses time to commercialization — it does not eliminate capital intensity thereafter and could saddle the company with high post-approval trial costs.

From a risk/return lens the name offers asymmetric upside on binary clinical successes but concentrated downside from funding failure or a small-sample clinical reversal. The market may be underpricing the optionality if the combination proves reproducibly able to convert partial responders to deep MRD negativity across multiple B-cell subtypes; conversely it may be overpricing early small-cohort signals that historically failed to scale in larger, controlled settings.

Key Decisions for Investors

• Tactical options spread — Buy a calendar or vertical call spread on CRIS (expiry 9–15 months) sized small relative to portfolio (<=1% equity exposure). Objective: capture re-rate from clinical readouts while capping premium paid. Risk/reward: limited downside = premium; upside = 3x–6x if a clear positive registrational signal and ASH data accelerate partnering interest.
• Equity + hedge — Initiate a modest long position in CRIS (~1–2% of biotech allocation) and buy 4–6 month protective puts (or construct a collar) to limit downside from a financing/dilution event. Rationale: preserves upside to binary clinical milestones while limiting tail loss if milestone-linked tranche fails to materialize.
• Relative/event pair — Long CRIS call spread vs short a small notional of a BTKi incumbent (e.g., ABBV) to isolate readout-specific alpha from broader market moves. This reduces market beta; profit if CRIS demonstrates differentiation and the incumbents’ chronic revenue model is re-rated downward. Size: net delta-neutral and small notional given cross-company execution risk.
• Liquidity watch / stop — Set a hard stop or liquidity trigger: if milestone funding is delayed >90 days from expected window, reduce exposure by 50% and reassess cash runway signals. Rationale: milestone delays materially increase dilution probability and compress positive skew of the trade.